Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by SABBOBCATon Nov 12, 2019 11:04am
179 Views
Post# 30339839

RE:RE:RE:RE:New Madrigal AASLD Slide on CV & NAFLD

RE:RE:RE:RE:New Madrigal AASLD Slide on CV & NAFLDDid you approach him or did he approach you?

SPCEO1 wrote: No, I have only met with MDGL's CFO so far.

palinc2000 wrote:

Have you met their CEO?
 

 

SPCEO1 wrote: Anyone else notice a very big difference in quality between MDGL's presentation and a TH presentation? MDGL is a very well-managed company. I have met the MDGL CFO and he is very impressive. TH is great and I respect all they have done, but these two companies are just in two different categories of excellence. It is one reason why I would love it if MDGL saw value in Egrifta and made a stock bid for TH as I feel the chances of Egrifta reaching it maximum potential would be much higher under MDGL's stewardship. Now, that is just wishful thinking, but when I see their presentations or meet with their CFO, it is only natural to desire such an outcome. 

That is all off topic, but it is the first reaction I had to looking at the MDGL presentation. Hopefully, TH can learn something from them.   
 

 

Wino115 wrote: Here's the slides presented today talking about Cardio risk and relationship with NAFLD.  Some strong slides also saying there's a need to act.  I haven't really read them thoroughly.

Madrigal MAESTRO NAFLD & CV Risk


 

 




Bullboard Posts